The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
How does transfusion independence impact survival outcomes with momelotinib in MF?
Featured:
Ruben A. MesaDuring ASCO and EHA 2021, the MPN Hub spoke with Ruben A Mesa, UT Health San Antonio, San Antonio, US. We asked, How does transfusion independence impact survival outcomes with momelotinib in myelofibrosis (MF)?
How does transfusion independence impact survival outcomes with momelotinib in MF?
Momelotinib is a JAKi that attenuates anemia in patients with MF. Mesa describes an analysis of the SIMPLIFY-1 study, comparing momelotinib with ruxolitinib in the frontline setting, and presents the correlation between transfusion-independent response and overall survival (OS) with momelotinib treatment.